No Data
Wanbang Pharmaceutical (301520.SZ): The clinical trial research and pharmaceutical research projects include those related to respiratory infection Pharmaceuticals, such as aminophylline tablets and others.
On January 9, Gelonghui reported that Wanbang Pharmaceutical (301520.SZ) stated on the investor interaction platform that the company's clinical trial research and pharmaceutical research projects involve Pharmaceuticals related to respiratory infections, such as aminophylline tablets, but the company does not engage in production and sales.
Wanbang Medicine (301520.SZ) has proposed a profit distribution plan for the first three quarters of 2024: intending to distribute 3.5 yuan for every 10 shares.
On December 30, Grandview Holdings announced that Wanbang Pharmaceutical (301520.SZ) proposed a profit distribution plan for the first three quarters of 2024: Based on the total share capital of 66,666,667 shares as of September 30, 2024, minus the 28,000 shares currently repurchased by the company, the total share capital will be 66,638,667 shares. A cash dividend of 3.5 RMB (tax included) will be distributed for every 10 shares to all shareholders, totaling a cash dividend of 23,323,533.45 RMB. There will be no bonus shares distributed and no capital reserve transferred into share capital, while the remaining distributable profits will be used for the company's development.
Wanbang Pharmaceutical (301520.SZ): First repurchase of 0.0168 million shares involving 0.6853 million yuan.
On December 18, Gelonghui reported that Wanbang Pharmaceutical (301520.SZ) announced that on December 17, 2024, the company repurchased 0.0168 million shares of its stock through a dedicated securities repurchase account via centralized bidding, accounting for 0.03% of the company's current total share capital. The highest Fill Price was 40.8 yuan per share, the lowest Fill Price was 40.72 yuan per share, and the transaction amount was 0.685259 million yuan (excluding transaction fees).
Wanbang Pharmaceutical (301520.SZ): Share buyback has not yet been implemented.
Gelonghui, December 3rd丨Wanbang Pharmaceutical (301520.SZ) announced that as of November 30, 2024, the company has not yet implemented a share buyback.
Wanbang Pharmaceutical (301520.SZ): Not producing polysulfated glycosaminoglycan cream at this time.
On December 3, Bioon Pharma (301520.SZ) stated on the investor interaction platform that the company is not currently producing heparin polysaccharide cream.
Wanbang Pharmaceutical (301520.SZ): Hefei Quanxiang plans to participate in a 10 million yuan private equity fund investment, laying out the field of cell and gene industry.
Wanbang Medicine (301520.SZ) announced that the Hefei Qunxiang Qiming Enterprise Management Partnership (Limited Partnership) controlled by the company...
